Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -438.15M | $ -270.21M | $ -208.28M | $ -156.03M | $ -108.12M |
| EBITDA | $ -437.77M | $ -269.98M | $ -208.08M | $ -155.91M | $ -108.05M |
| Net Income | $ -413.84M | $ -259.34M | $ -210.96M | $ -156.73M | $ -107.43M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 713.97M | $ 635.37M | $ 376.53M | $ 493.82M | $ 400.15M |
| Total Assets | $ 776.22M | $ 666.71M | $ 405.84M | $ 515.56M | $ 412.49M |
| Total Debt | $ 98.00K | $ 138.00K | $ 1.22M | $ 2.36M | $ 3.42M |
| Net Debt | $ -713.87M | $ -635.23M | $ -375.31M | $ -491.45M | $ -396.73M |
| Total Liabilities | $ 68.78M | $ 48.95M | $ 43.34M | $ 45.74M | $ 21.01M |
| Stockholders' Equity | $ 707.45M | $ 617.76M | $ 362.49M | $ 469.82M | $ 391.48M |
| Cash Flow | |||||
| Free Cash Flow | $ -376.63M | $ -214.59M | $ -188.39M | $ -106.37M | $ -83.54M |
| Operating Cash Flow | $ -375.87M | $ -214.23M | $ -188.19M | $ -106.11M | $ -83.33M |
| Investing Cash Flow | $ -759.00K | $ -360.00K | $ -197.00K | $ -254.00K | $ -210.00K |
| Financing Cash Flow | $ 454.49M | $ 472.43M | $ 70.89M | $ 200.13M | $ 383.11M |
Immunovant Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.